New
drug development is a high-
risk venture, but if successful,
will bring great revenues to those willing to accept the
risk. In the field of
urology, in particular for
lower urinary tract symptoms (LUTS), the recent successful landing of
drugs (e.g., mirabegron,
botulinum toxin A, and
tadalafil) has resulted in increased interest in new
drug development.
Benign prostatic hyperplasia and
overactive bladder syndrome, representative LUTS
diseases, are attractive targets because of their
prevalence and market size in the field of
urology. Additionally, the
awareness about new
stream of
research is very important not only because of the market size and
economic factors, but also because to keep steady
attention to these
research for the
researcher’s. We have reviewed a selection of
new drugs currently under development for the
treatment of the two aforementioned
diseases and
hope to offer
urologists an overview of the current situation and
future directions in the field of
urology.